CINCINNATI, Jan 10 (Bernama-GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned
subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the
expansion of the EPIK™ miRNA Select Assays, originally developed for the study
of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline
released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased
to include all of the organisms listed on the miRBase release 21, which
represents over 27,000 miRNA assays. Recent studies continue to show the
clinical value of individual miRNA molecules which are released from tissues
and cells. The expression of certain individual miRNA molecules correlates with
specific disease conditions making them promising biomarker candidates for the
early detection of disease, prognosis and monitoring of treatment in both
humans and other organisms.
No comments:
Post a Comment